Health-related quality of life in cancer patients treated with immune checkpoint inhibitors in randomised controlled trials: A systematic review and meta-analysis
Open Access
- 1 December 2021
- journal article
- review article
- Published by Elsevier in European Journal of Cancer
- Vol. 159, 154-166
Abstract
No abstract availableKeywords
This publication has 41 references indexed in Scilit:
- Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments ReceivedJournal of Clinical Oncology, 2016
- American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment OptionsJournal of Clinical Oncology, 2015
- A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS)Annals of Oncology, 2015
- Health-related quality of life impact in a randomised phase III study of the combination of dabrafenib and trametinib versus dabrafenib monotherapy in patients with BRAF V600 metastatic melanomaEuropean Journal of Cancer, 2015
- Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC studyAnnals of Oncology, 2014
- Health-related quality of life and cancer clinical trialsTherapeutic Advances in Medical Oncology, 2011
- The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaborationJournal of Clinical Epidemiology, 2009
- EQ-SD: a measure of health status from the EuroQol GroupAnnals of Medicine, 2001
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI: Journal of the National Cancer Institute, 1993
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986